MedTrace Logo

Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint

NCT06981741 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-01-13

No results posted yet for this study

Summary

Testing the safety and efficacy of MSC from umbilical cord tissue (UC-MSC) for the treatment of cartilage damage in the knee joint

Conditions

  • Cartilage Damage

Interventions

BIOLOGICAL

BP CC 001

10-20 x 10\^6 UC-MSC in 1 ml suspension, applied to a collagen carrier structure (Chondro-Gide®)

Sponsors & Collaborators

  • KKS Netzwerk

    collaborator NETWORK

  • Fraunhofer Institute for Cell Therapy and Immunology IZI

    collaborator UNKNOWN

  • Polski Bank Komorek Macierzystych JSC (PBKM)

    collaborator INDUSTRY

  • BIONCaRT GmbH

    lead INDUSTRY

Principal Investigators

  • Jörg Lützner, Prof.Dr.med. · UniversitätsCentrum für Orthopädie, Unfall- & Plastische Chirurgie, Universitätsklinikum Carl Gustav Carus, TU Dresden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-10
Primary Completion
2027-11-30
Completion
2028-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06981741 on ClinicalTrials.gov